[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-365661-en":59,"doc-seo-365661-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},365661,962084926284,"Aria Callaghan","https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy","Immunotherapies that target the programmed cell death-1 ligand 1 (PD-L1) and programmed cell death 1 (PD-1) pathway have transformed cancer treatment by blocking PD-1 on T cells from engaging PD-L1 on cancer cells. This disruption unleashes T-cell effector activity, but PD-L1 also carries functions beyond immune evasion. PD-L1 transmits inhibitory signals through PD-1, while additionally mediating reverse/intrinsic signaling in cancer cells. The review surveys how PD-L1 intrinsic signaling supports survival, proliferation, DNA damage responses, and transcriptional regulation, and outlines emerging therapeutic opportunities.","Review  \nProgrammed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy  \nDavid Escors *, Luisa Chocarro, Miriam Echaide , Claudia Rodriguez-Neira, Borja Vilaplana  and Grazyna Kochan *  \nAcademic Editor: Constantin  \nN. Baxevanis  \nReceived: 10 March 2025  \nRevised: 29 April 2025  \nAccepted: 9 May 2025  \nPublished: 12 May 2025  \nCitation: Escors, D.; Chocarro, L.; Echaide, M.; Rodriguez-Neira, C.; Vilaplana, B.; Kochan, G. Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy. Cancers 2025, 17, 1635 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17101635  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nOncoImmunology Unit, Navarrabiomed-Fundacion Miguel Servet, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdISNA), Universidad Publica de Navarra (UPNA),  \n31008 Pamplona, Spain; [miriam.echaide.gorriz@navarra.es](miriam.echaide.gorriz@navarra.es) (M.E.); [claudia.rodriguez.neira@navarra.es](claudia.rodriguez.neira@navarra.es) (C.R.-N.); [borja.vilaplana.marti@navarra.es](borja.vilaplana.marti@navarra.es) (B.V.)  \n* Correspondence: descorsm@navarra.es (D.E.); grazyna.kochan@navarra.es (G.K.)  \nSimple Summary: Immune checkpoint blockade therapies transformed clinical oncology. However, much is unknown of the cellular and immunological mechanisms behind its success. In recent years, extensive research on the mechanisms of action of programmed death-1 ligand 1 (PD-L1) uncovered the multiple facets of this immune checkpoint molecule on the biology of the cell. Here we review the current knowledge on PD-L1 structure, signaling motifs and interactors that provide a mechanistic insight into the functions of this key immune checkpoint.  \nAbstract: Immunotherapies targeting the programmed cell death-1 ligand 1 (PD-L1) and programmed cell death 1 (PD-1) pathway sparked a revolution in cancer treatment. These breakthrough therapies work by disrupting the interaction between PD-1—expressed on T cells—and its ligand PD-L1, commonly found on the surface of cancer cells. By using monoclonal antibodies to block this binding, the immune system is unleashed to fight cancer more effectively. However, PD-L1’s role extends far beyond immune evasion. When situated on cancer cells, PD-L1 transmits inhibitory signals through PD-1, silencing the effector functions of T cells. However, PD-L1 also engages in reverse signaling, also called intrinsic signaling, delivering intracellular instructions that contribute to cancer cell survival, even in the absence of PD-1 binding. This signaling cascade shields cancer cells from apoptosis, drives proliferation, regulates DNA damage responses, and even functions as a co-transcriptional transactivator, amplifying cancer’s ability to thrive. The intricate mechanisms behind PD-L1’s intrinsic signaling are under intense investigation. In this review, we provide a historical perspective on the discoveries leading to PD-L1’s structure, signaling motifs, and interacting partners, shedding light on its multifaceted roles and the promising therapeutic possibilities ahead.  \nKeywords: cancer immunotherapy; immune checkpoint blockade; signal transduction pathways  \n1. Introduction  \nNot so long ago, cancer immunotherapies were not considered serious therapeutic options by most oncologists or researchers in oncology. Development of antineoplastic treatments was largely devoted to engineering small molecules and kinase inhibitors targeting cancer cell growth and survival pathways [1–4] . Cancer cells were the targets, and pharmaceutical companies invested sig","cbCaimmaCP2zb1pi","https://ap.wps.com/l/cbCaimmaCP2zb1pi","pdf",1999210,21,"English","en",105,"# Introduction\n## PD-1/PD-L1 discovery and early immunotherapies\n## Impact of CTLA-4 blockade and rise of PD-1/PD-L1 trials\n## PD-L1 functions: immune inhibitory and intrinsic signaling","[{\"question\":\"How do PD-1 and PD-L1 interactions influence T-cell function in cancer?\",\"answer\":\"PD-L1 on cancer cells binds PD-1 on T cells to deliver inhibitory signals, silencing T-cell effector functions and promoting immune suppression.\"},{\"question\":\"What is described as PD-L1 reverse or intrinsic signaling?\",\"answer\":\"Beyond immune evasion, PD-L1 can trigger reverse/intrinsic intracellular signaling within cancer cells, sending instructions that affect key cellular behaviors.\"},{\"question\":\"Which cellular processes are linked to PD-L1 intrinsic signaling in the review?\",\"answer\":\"The document links PD-L1 intrinsic signaling to resistance to apoptosis, proliferation support, regulation of DNA damage responses, and transcription-related transactivation effects.\"}]","Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy | PDF",1790161661,53,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d7e47f5a014ba11754cd7ed44b04108.webp",983,1390,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f83f749a3c9ae32559cd58effb5ca6dd.webp",982,1388,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1ed8c3cd8154a17237779a0f8ca49ff.webp",981,1387,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe2abd531b34b00012abd93c9b05046f.webp",980,1385,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"programmed-death-1-ligand-1-domain-organization-signaling-motifs-and-interactors-in-cancer-immunotherapy","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/programmed-death-1-ligand-1-domain-organization-signaling-motifs-and-interactors-in-cancer-immunotherapy/365661/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/programmed-death-1-ligand-1-domain-organization-signaling-motifs-and-interactors-in-cancer-immunotherapy/365661.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":136,"interactionType":137,"userInteractionCount":29},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"How do PD-1 and PD-L1 interactions influence T-cell function in cancer?","Question",{"text":146,"@type":147},"PD-L1 on cancer cells binds PD-1 on T cells to deliver inhibitory signals, silencing T-cell effector functions and promoting immune suppression.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"What is described as PD-L1 reverse or intrinsic signaling?",{"text":151,"@type":147},"Beyond immune evasion, PD-L1 can trigger reverse/intrinsic intracellular signaling within cancer cells, sending instructions that affect key cellular behaviors.",{"name":153,"@type":144,"acceptedAnswer":154},"Which cellular processes are linked to PD-L1 intrinsic signaling in the review?",{"text":155,"@type":147},"The document links PD-L1 intrinsic signaling to resistance to apoptosis, proliferation support, regulation of DNA damage responses, and transcription-related transactivation effects.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790195080]